Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
CNY 31.24
(-0.13%)
CNY 31.24
(-0.13%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 275.25 Million | 151.94 Million | 147.59 Million | 156.52 Million | 141.83 Million | 166.78 Million |
| Net Income | 226.57 Million | 246.52 Million | 232.42 Million | 178.16 Million | 108.61 Million | 135.02 Million |
| Depreciation & Amortization | 73.23 Million | 58.34 Million | 32.6 Million | 32.97 Million | 27.5 Million | 25.35 Million |
| Deferred income taxes | 735.23 Thousand | 4.19 Million | -3.31 Million | -5.31 Million | 521.77 Thousand | 534.1 Thousand |
| Stock-based compensation | 254.55 Thousand | - | - | - | 28.27 Million | 1.5 Million |
| Change in working capital | -7.52 Million | -132.4 Million | -77.05 Million | -47.82 Million | -21.88 Million | 4.88 Million |
| Other non-cash items | 5 Million | -20.52 Million | -40.38 Million | -6.78 Million | -1.19 Million | 1.52 Million |
| Investing Cash Flow | -410.17 Million | -405.7 Million | -110.58 Million | -756.62 Million | -87.99 Million | -74.8 Million |
| Investments in PPE | -175.26 Million | -339.32 Million | -256.29 Million | -198.8 Million | -95.41 Million | -76.63 Million |
| Acquisitions | 262.65 Thousand | 331.2 Thousand | -160.61 Million | 99.26 Thousand | 50.1 Thousand | - |
| Investment purchases | -34.5 Million | -120 Million | -4.04 Billion | -2.26 Billion | -1.22 Billion | - |
| Sales/Maturities of investments | - | 73.79 Million | 4.2 Billion | 1.7 Billion | 1.23 Billion | - |
| Other Investing Activities | -200.67 Million | -20.49 Million | 145.7 Million | 1.82 Million | 120 Thousand | 1.82 Million |
| Financing Cash Flow | 80.67 Million | 39.69 Million | -56.39 Million | 1.25 Billion | -13.85 Million | - |
| Debt repayment | -143.52 Million | -50 Million | -50 Million | -36.05 Million | -8.64 Million | - |
| Dividends payments | -67.25 Million | -93.67 Million | -36.02 Million | -696.28 Thousand | -22.5 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | -27.87 Million | - | - |
| Other Financing Activities | 8.22 Million | 185.74 Million | 30 Million | 1.25 Billion | 17.28 Million | - |
| Accounts receivables | -75.72 Million | -51.53 Million | -181.32 Million | -121.68 Million | -48.29 Million | -42.62 Million |
| Accounts payables | 90.2 Million | -45.56 Million | 129.13 Million | 104.75 Million | 37.62 Million | 47.5 Million |
| Inventory | -22.73 Million | -39.5 Million | -21.55 Million | -25.58 Million | -11.73 Million | -529.33 Thousand |
| Other working capital | 1.22 Million | 4.19 Million | -3.31 Million | -5.31 Million | 521.77 Thousand | 5.41 Million |
| Cash at beginning of period | 821.85 Million | 1.03 Billion | 1.05 Billion | 404.05 Million | 364.05 Million | 272.03 Million |
| Cash at end of period | 767.54 Million | 821.85 Million | 1.03 Billion | 1.05 Billion | 404.05 Million | 364.05 Million |
| Capital Expenditure | -175.26 Million | -339.32 Million | -256.29 Million | -198.8 Million | -95.41 Million | -76.63 Million |
| Effect of forex changes on cash | -67.26 Thousand | 23.12 Thousand | -5185.70 | -24.62 Thousand | 25.08 Thousand | 33.17 Thousand |
| Net cash flow / Change in cash | -54.31 Million | -214.03 Million | -19.39 Million | 651.23 Million | 40 Million | 92.01 Million |
| Free Cash Flow | 99.99 Million | -187.38 Million | -108.69 Million | -42.28 Million | 46.41 Million | 90.15 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 70.53 Million | 71.48 Million | 75.01 Million | 226.57 Million | 32.57 Million | 62.19 Million |
| Depreciation & Amortization | - | 21.41 Million | 21.41 Million | 73.23 Million | 19.57 Million | -34.53 Million |
| Deferred income taxes | - | - | - | 735.23 Thousand | - | - |
| Stock-based compensation | - | - | - | 254.55 Thousand | 254.55 Thousand | - |
| Change in working capital | - | - | - | -7.52 Million | -97.23 Million | 7.89 Million |
| Other non-cash items | -9.86 Million | -35.97 Million | -3.11 Million | 5 Million | -32.57 Million | 38.21 Million |
| Investing Cash Flow | 11.56 Million | -209.09 Million | 41.29 Million | -410.17 Million | 122.37 Million | -226.55 Million |
| Investments in PPE | -21.32 Million | -28.66 Million | -41.32 Million | -175.26 Million | -22.88 Million | -59.76 Million |
| Acquisitions | 82.17 Thousand | 10.5 Thousand | 27.05 Thousand | 262.65 Thousand | 251.14 Thousand | - |
| Investment purchases | 1.01 Billion | -1.01 Billion | -1.5 Million | -34.5 Million | - | -18 Million |
| Sales/Maturities of investments | -914.26 Million | 914.26 Million | - | - | - | - |
| Other Investing Activities | 32.88 Million | -84.09 Million | 84.09 Million | -200.67 Million | 145.01 Million | -148.78 Million |
| Financing Cash Flow | -152.41 Million | 40.93 Million | -63.99 Million | 80.67 Million | 46.08 Million | 42.41 Million |
| Debt repayment | -60.98 Million | -1.47 Million | -10 Million | -143.52 Million | -38.52 Million | -10 Million |
| Dividends payments | -30.66 Million | -41.35 Million | -1.28 Million | -67.25 Million | -1.18 Million | -67.25 Million |
| Common Stock Repurchased | 52.71 Million | -52.71 Million | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -60.76 Million | 95.13 Million | -52.71 Million | 8.22 Million | 8.75 Million | 53.47 Million |
| Accounts receivables | - | - | - | -75.72 Million | -75.72 Million | -14.03 Million |
| Accounts payables | - | - | - | 90.2 Million | - | 881.93 Thousand |
| Inventory | - | - | - | -22.73 Million | -22.73 Million | 21.93 Million |
| Other working capital | - | - | - | 1.22 Million | 1.22 Million | -881.93 Thousand |
| Cash at beginning of period | 662.58 Million | 823.66 Million | 767.54 Million | 821.85 Million | 521.63 Million | 632.04 Million |
| Cash at end of period | 582.24 Million | 682.61 Million | 816.63 Million | 767.54 Million | 767.54 Million | 521.63 Million |
| Capital Expenditure | -21.32 Million | -28.66 Million | -41.32 Million | -175.26 Million | -22.88 Million | -59.76 Million |
| Effect of forex changes on cash | -164.92 Thousand | 25.81 Thousand | -97.93 Thousand | -67.26 Thousand | -58.72 Thousand | -46.33 Thousand |
| Net cash flow / Change in cash | -80.34 Million | -141.05 Million | 49.09 Million | -54.31 Million | 245.91 Million | -110.41 Million |
| Free Cash Flow | 39.34 Million | -14.57 Million | 30.56 Million | 99.99 Million | 54.61 Million | 14 Million |
SBW
HGYN
6692
200541
600789
1171